(-1.04%) 4 959.06 points
(0.28%) 37 882 points
(-2.23%) 15 254 points
(0.45%) $83.10
(-0.11%) $1.755
(0.51%) $2 410.20
(1.48%) $28.80
(-1.34%) $941.70
(-0.04%) $0.939
(-0.11%) $11.03
(0.56%) $0.808
(-0.93%) $93.02
Live Chart Being Loaded With Signals
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment...
Stats | |
---|---|
Today's Volume | 1.60M |
Average Volume | 116 814 |
Market Cap | 58.13B |
EPS | $20.84 ( 2023-09-30 ) |
Last Dividend | $0.119 ( 2021-09-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | 48.12 |
ATR14 | $0.0380 (0.13%) |
Volume Correlation
Daiichi Sankyo Company, Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Daiichi Sankyo Company, Correlation - Currency/Commodity
Daiichi Sankyo Company, Financials
Annual | 2023 |
Revenue: | $1 278.48B |
Gross Profit: | $914.95B (71.57 %) |
EPS: | $56.96 |
Q3 | 2023 |
Revenue: | $446.93B |
Gross Profit: | $324.58B (72.62 %) |
EPS: | $34.71 |
Q2 | 2023 |
Revenue: | $375.51B |
Gross Profit: | $280.77B (74.77 %) |
EPS: | $20.86 |
Q1 | 2023 |
Revenue: | $350.84B |
Gross Profit: | $257.16B (73.30 %) |
EPS: | $29.74 |
Financial Reports:
No articles found.
Daiichi Sankyo Company, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.122 | 2021-03-29 |
Last Dividend | $0.119 | 2021-09-28 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.241 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.7 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.25 | |
Div. Directional Score | 8.95 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OCPNF | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
DTRL | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
TKAGY | Ex Dividend Knight | 2023-06-12 | Annually | 0 | 0.00% | |
ITJTY | Ex Dividend Junior | 2023-10-31 | Annually | 0 | 0.00% | |
BORT | Ex Dividend Knight | 2023-08-10 | Quarterly | 0 | 0.00% | |
PTBS | Ex Dividend Knight | 2023-08-03 | Quarterly | 0 | 0.00% | |
FAXRF | Ex Dividend Junior | 2023-09-14 | Quarterly | 0 | 0.00% | |
UNCHF | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
KSBI | Ex Dividend Knight | 2023-07-28 | Quarterly | 0 | 0.00% | |
CKHGY | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.124 | 1.500 | 7.53 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0569 | 1.200 | 8.10 | 9.72 | [0 - 0.3] |
returnOnEquityTTM | 0.121 | 1.500 | 9.77 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.362 | -1.000 | 6.38 | -6.38 | [0 - 1] |
currentRatioTTM | 3.49 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.77 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.099 | 1.500 | 5.01 | 7.51 | [0.2 - 2] |
debtRatioTTM | 0.0349 | -1.500 | 9.42 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 10.54 | 1.000 | 7.21 | 7.21 | [3 - 30] |
operatingCashFlowPerShareTTM | 313.79 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 265.71 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0720 | -1.500 | 9.71 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.723 | 1.000 | 1.286 | 1.286 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.125 | 1.000 | 9.50 | 9.50 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 5.27 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.460 | 0.800 | -0.267 | -0.214 | [0.5 - 2] |
Total Score | 12.64 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 46.37 | 1.000 | 5.42 | 0 | [1 - 100] |
returnOnEquityTTM | 0.121 | 2.50 | 9.85 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 265.71 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.00200 | 1.500 | 9.95 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 313.79 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.362 | 1.500 | 6.38 | -6.38 | [0 - 1] |
pegRatioTTM | 0.00481 | 1.500 | -3.30 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.400 | 1.000 | 2.50 | 0 | [0.1 - 0.5] |
Total Score | 5.25 |
Daiichi Sankyo Company,
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators